RE: Broker taregt $1 billion5 Dec 2019 11:55
this says it all really.... they might not see as much benefit in the 2019 annual results, but the outlook for 2020 and beyond is very promising.
“Demand for the company’s products remains strong and the board does not anticipate any longer term impact over and above the approximate three-month delay to the manufacturing capacity increase.”
Tissue Regenix has also received confirmation of a $0.3m grant from Universal City to support the initial phase of the build out programme on the company’s newly leased 21,000 sq ft facility in San Antonio in the US.
The statement added: “Technical staff necessary to enable the second shift in the original San Antonio facility to become operational have been recruited and are in the process of being trained.
“Monthly processing throughput has already more than doubled in the year to Q3 and these additional products are expected to become available towards the end of Q4.
“The company is working closely with its existing outsource provider, CTS, in order to increase the yield of its DermaPure product after also announcing the launch of DermaPure Non-Oriented, for use in surgical and uro-gynaecology applications, at the American Urogynecologic Society conference in Nashville in September.”
“The company is working closely with its strategic partner, ARMS Medical, on the roll-out of this product.”
John Samuel, executive chairman, of Tissue Regenix, said: “We have excellent products for which demand is exceeding our current capacity. Therefore, our current focus is ensuring we can increase our capacity to meet this significant demand.”